Compare · AWH vs ORKA
AWH vs ORKA
Side-by-side comparison of Aspira Women's Health Inc. (AWH) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AWH and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $5.72B, about 47.2x AWH ($121.1M).
- ORKA has hit the wire 2 times in the past 4 weeks while AWH has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 1 for AWH).
- Company
- Aspira Women's Health Inc.
- Oruka Therapeutics Inc.
- Price
- $0.08-9.52%
- $98.08+3.40%
- Market cap
- $121.1M
- $5.72B
- 1M return
- -
- +17.85%
- 1Y return
- -
- +585.19%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 2
- Recent ratings
- 1
- 11
Aspira Women's Health Inc.
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. It provides OVA1, Overa, and Ova1PLUS to detect the risk of ovarian malignancy. The company also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, it owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, the company is developing diagnostic algorithms; and a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. It has entered into a collaborative research agreement with Baylor Genetics to co-develop a novel ovarian cancer early-detection test; and an agreement with Dana Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer. The company has a strategic alliance with Quest Diagnostics, Incorporated. It serves physician office and hospital laboratories, as well as physicians. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.
Latest AWH
- Aspira Women's Health and Cleveland Clinic Expand Strategic Collaboration to Advance AI-Powered Diagnostics in Women's Health
- Aspira Women's Health (OTCQB:AWHL) Enters Key Growth Phase with Molecular Lab Expansion to Accelerate Breakthrough Endometriosis Blood Test ENDOinform(TM)
- Aspira Announces Third Quarter 2025 Financial Results and Provides Business Update
- Aspira Women's Health Wins Laboratory Service Contract with University of Texas Medical Branch at Galveston
- Aspira Women's Health Announces Equity Capital Infusion of $3.06 Million in Private Placement and Warrant Exercise
- Aspira Women's Health Appoints New Chief Financial Officer
- Aspira Announces Second Quarter 2025 Financial Results and Provides Business Update
- Aspira Women's Health Announces Appointment of Jane Pine Wood to the Board of Directors
- Aspira Women's Health Partners with Dorsata to Offer Access to 300+ Women's Health Practices, 1.5 Million + New Patients
- Aspira Women's Health Provides Update on ARPA-H Sprint Program Partnership to Advance Women's Health
Latest ORKA
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $603,938 worth of shares (7,000 units at $86.28) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,999 shares at a strike of $15.69 and sold $846,180 worth of shares (9,999 units at $84.63) as part of a pre-agreed trading plan (SEC Form 4)
- Director Fairmount Funds Management Llc converted options into 3,553,410 shares and sold $300,014,406 worth of shares (3,553,410 units at $84.43) (SEC Form 4)
- Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $472,079 worth of shares (5,000 units at $94.42) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun sold $128,468 worth of shares (1,587 units at $80.95) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 15,312 units (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,459 shares at a strike of $15.88 and sold $687,035 worth of shares (9,854 units at $69.72) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 16,899 units (SEC Form 4) to cover taxes
- Chief Medical Officer Goncalves Joana sold $550,607 worth of shares (7,947 units at $69.28) as part of a pre-agreed trading plan and exercised 7,000 shares at a strike of $7.32, decreasing direct ownership by 3% to 32,718 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Klein Lawrence Otto sold $120,494 worth of shares (1,729 units at $69.69), decreasing direct ownership by 0.19% to 925,580 units (SEC Form 4) to cover taxes
- Chief Operating Officer Sandler Laura Lee sold $41,814 worth of shares (600 units at $69.69), decreasing direct ownership by 0.25% to 236,384 units (SEC Form 4) (for tax liability)
- General Counsel Quinlan Paul T sold $51,083 worth of shares (733 units at $69.69), decreasing direct ownership by 2% to 31,034 units (SEC Form 4) (for withholding tax)